急性冠脉综合征患者中氯吡格雷抵抗的发生率及影响因素Incidence rates of clopidogrel resistance and influential factors in patients with acute coronary syndrome
王明亮;朱毅;甘洁民;
摘要(Abstract)：
目的探讨急性冠状动脉综合征(ACS)患者中氯吡格雷抵抗(CPGR)的发生率及影响因素。方法入选100例拟行经皮冠状动脉介入治疗(PCI)的ACS患者,服用负荷量氯吡格雷(CPG)前、服药后24 h分别采血,利用光比浊法测定血浆二磷酸腺苷(ADP)诱导的血小板聚集率(PA),根据PA抑制程度判断CPGR发生率,并据此分为CPGR组和非CPGR组。对ACS患者临床危险因素与CPGR进行相关分析。结果 100例ACS患者中有23例发生CPGR,CPGR发生率为23%。CPGR组和非CPGR组在基线临床特征和合并用药方面差异均无统计学意义(P>0.05)。但CPGR组基线PA明显低于非CPGR组(P<0.05),基线PA是CPGR的独立预测指标。结论 ACS和PCI术后抗血小板治疗中,部分患者确实存在CPGR现象。基线PA水平对CPGR具有重要的预测价值。
关键词(KeyWords)： 急性冠脉综合征;氯吡格雷;药物抵抗;血小板聚集率;影响因素
基金项目(Foundation):
作者(Author): 王明亮;朱毅;甘洁民;
Email:
DOI: 10.19577/j.cnki.issn10074406.2010.03.002
参考文献(References)：
- [1]Gurbel PA,Bliden KP,Hiatt Bl,et al.Clopidogrel for coronary stenting: response variability drug resistance and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908.
- [2]CAPRIE Steering Committee.A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events[J].Lancet,1996, 348(9068):1329.
- [3]The CURE Investigation.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med,2001,345(7):494.
- [4]Mehta SR,Yusuf S,Peter RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study[J].Lancet, 2001,358:527.
- [5]Steinhubl SR,Berger PB,Mann JT,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J].J Am Med Assoc,2002,288:2411.
- [6]Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cytochrome p450 3A4 metabolic activity to the phenomenon of clopidogrel resistance[J].Circulation,2004,109(2):166.
- [7]Mitsios JV,Papathanasiou AP,Rodis FI,et al.Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes[J]. Circulation,2004,109(11):1335.
- [8]Forbes CD,Lowe GD,Maclaren M,et al.Clopidogrel compatibility with concomitant cardiac co-medications:a study of its interactions with a beta-blocker and a calcium uptake antagonist[J].Semin Thromb Hemost,1999,5(Supply 2):55.
- [9]郭丽敏,崔炜,杨晓红,等.氯吡格雷抵抗的发生率及其影响因素[J].河北医科大学学报,2008,29(4):497.
- [10]Ho PM,Maddox TM,Wang L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2009,301(9):937.
- [11]Juurlink DN,Gomes T,Ko DT,etal.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. Can Med Assoc J,2009,180(7):713.